Drug: Rapamycine

What It Is

Rapamycin is a compound first isolated in the twentieth century from a soil bacterium found on Easter Island. Its name comes from the island's local name, Rapa Nui. As the drug sirolimus, it has been used in medicine for decades. Its main job there is to suppress the immune system after an organ transplant, so the body does not reject the new organ. It also coats the stents that hold coronary arteries open. Two close relatives, everolimus and temsirolimus, treat certain cancers and the rare disease tuberous sclerosis.

Rapamycin became the most discussed molecule in aging research for a reason separate from all of that. It acts on a growth-control pathway called mTOR, and dialing that pathway down is the intervention the whole longevity case rests on. That has produced a large and growing off-label use: people take rapamycin hoping to slow their own aging, well ahead of any human trial.

Anatomy

1The mTOR pathway

mTOR, the mechanistic target of rapamycin, is a master growth switch inside every cell. It senses nutrients and growth signals and, when they are plentiful, drives the cell to build proteins and grow while holding back cellular recycling. Turning mTOR down slows growth and steps up autophagy, the process that clears out worn-out cellular parts. This is the pathway the whole longevity case runs through.

2Sirolimus, the original drug

Sirolimus is rapamycin as a licensed medicine. It is given orally to prevent kidney transplant rejection and to treat the rare lung disease lymphangioleiomyomatosis, and it coats drug-eluting cardiac stents. It is the form with the longest human safety record, gathered mostly in transplant patients taking it continuously at doses set to suppress the immune system.

3Everolimus and the analogues

Everolimus and temsirolimus are chemical relatives of rapamycin, the class often called rapalogs. Everolimus is approved for several cancers, for tuberous sclerosis, and in transplant medicine. In aging research the low-dose, short-course use of everolimus is what produced the human immune findings, at doses well below those used to prevent transplant rejection.

How It Works

Rapamycin inhibits mTOR complex 1, the branch of the mTOR pathway that governs cell growth. It acts indirectly. The drug first binds a small intracellular protein called FKBP12. That pair then latches onto mTOR complex 1 and shuts much of its activity down.

When mTOR complex 1 is active, the cell responds as if nutrients are abundant: it builds proteins, grows, and slows recycling. Inhibiting the complex reverses that: the cell lowers its building and switches on autophagy, the housekeeping process that breaks down and recycles damaged parts. The result reproduces much of the cellular state that fasting produces.

That link is why aging biology keeps returning to the drug. Nutrient sensing is one of the recognized hallmarks of aging, and mTOR is its central node. A drug that turns the node down is a direct test of the idea that dialing back growth signaling slows aging. For where mTOR fits among the other drivers, see the biology of aging.

Prolonged or higher-dose rapamycin also disturbs a second complex, mTOR complex 2. That second effect is tied to the drug's influence on blood sugar and insulin. It is the mechanism behind the metabolic risks listed later.

What It Does

The animal record is the strongest in longevity research. In the National Institute on Aging Interventions Testing Program, rapamycin extended the lifespan of genetically diverse mice. The program runs each compound at three separate laboratories to screen out fluke results, and the rapamycin result held up to replication. It worked even when treatment began at roughly the human equivalent of age 60. No other longevity molecule has an animal record this consistent, which is why the mouse findings sit at the top of the ladder below. Still, a lifespan gain in mice is a reason to study the drug in people. It is not yet proof of anything in humans.

The human evidence sits lower. It measures immunity and feasibility, and it has not measured lifespan at all. No completed trial has tested whether rapamycin extends human life or healthspan. The signals that exist are narrow immune findings in adults over 65, measured over weeks to a year. One large phase-3 trial of the mTOR inhibitor RTB101, given on its own, missed its main infection endpoint. So the human evidence is still preliminary. Trials of physical function in healthy people are small and early.

Most of what is known about rapamycin's side effects comes from the approved uses. There, sirolimus, everolimus, and temsirolimus are dosed continuously, at levels set to suppress the immune system or hold back a tumor. None of those licensed indications is aging.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

How it works

Rapamycin inhibits mTORC1, mimicking mild fasting and switching on autophagyStrong · mixed

In plain terms

Rapamycin turns down mTOR, the master switch a cell uses to sense nutrients and balance growth against recycling. Turning it down mimics mild fasting and steps up autophagy, the recycling of worn-out parts.

In detail

Rapamycin (sirolimus) forms a complex with the 12 kDa FK506-binding protein (FKBP12) that binds and inhibits mTOR complex 1. mTORC1 integrates signals from amino acids, growth factors and energy status to drive ribosome biogenesis, protein and lipid synthesis, and cell growth, and it suppresses macroautophagy. Inhibiting mTORC1 therefore lowers anabolic activity and de-represses autophagy, reproducing much of the cellular state that nutrient scarcity and caloric restriction produce. Prolonged or higher-dose exposure also affects the second complex, mTORC2, which is relevant to the metabolic effects seen with the drug.

The study · 1

Saxton and Sabatini, mTOR Signaling in Growth, Metabolism, and Disease · Cell 2017;169(2):361-371

Respiratory Infection

A low-dose mTOR inhibitor cut respiratory infections in older adults over the following yearModerate

In plain terms

In a larger follow-up trial, a low-dose mTOR inhibitor lowered the number of respiratory infections in older adults across a year. It is the strongest human signal that turning mTOR down can support immune function with age.

In detail

Mannick and colleagues (2018) randomized 264 older adults to combinations of the mTOR inhibitor RTB101 and everolimus or to placebo and followed respiratory tract infections over a year. The regimen that combined low doses of both drugs reduced the rate of laboratory-confirmed respiratory infections and was associated with an upregulated antiviral gene signature, extending the earlier vaccine finding to a clinical infection endpoint.

The study · 1

Mannick et al., TORC1 inhibition enhances immune function and reduces infections in the elderly · Sci Transl Med 2018;10(449):eaaq1564

Blood Sugar

Chronic rapamycin caused insulin resistance in mice by disrupting mTORC2Moderate · risk

In plain terms

Long-term rapamycin can cause insulin resistance, and in mice this comes from hitting a second mTOR complex. It suggests the metabolic downside and the longevity benefit may run through different branches of the pathway.

In detail

Lamming and colleagues (2012) showed that chronic rapamycin in mice disrupts mTOR complex 2 (mTORC2) in addition to mTORC1, and that the loss of mTORC2 signaling in the liver drives the glucose intolerance and insulin resistance seen with the drug. Because lifespan extension is attributed mainly to mTORC1 inhibition, the work raised the prospect that the metabolic cost and the longevity benefit are, at least in principle, separable.

The study · 1

Lamming et al., Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity · Science 2012;335(6076):1638-1643

Rapamycin left mice glucose intolerant yet still insulin sensitiveModerate · mixed

In plain terms

Rapamycin's effect on blood sugar in mice is mixed: it worsens glucose handling on one test while preserving insulin sensitivity on another. The metabolic picture is more complicated than a single label.

In detail

Lamming and colleagues (2013) found that young and old genetically heterogeneous mice fed rapamycin were glucose intolerant on a glucose challenge yet stayed insulin sensitive, an uncoupling that does not match the usual pattern of type 2 diabetes. The finding sharpens the metabolic question, not dismissing it, because glucose intolerance, raised triglycerides and cholesterol are also documented in people who take the drug for organ transplant.

The study · 1

Lamming et al., Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive · Aging Cell 2013;12(4):712-718

Immune Function

Six weeks of an mTOR inhibitor raised older adults' flu-vaccine antibody response about 20%Emerging

In plain terms

A short course of an mTOR inhibitor improved how well older adults responded to a flu vaccine. This is a narrow human immune finding, not evidence about lifespan.

In detail

Mannick and colleagues (2014) randomized 218 adults aged 65 and older to low doses of the rapamycin analogue everolimus or placebo for six weeks before seasonal influenza vaccination. Low-dose everolimus improved the antibody response to the vaccine by roughly 20% and reduced the proportion of exhausted, senescent immune cell subsets, suggesting mTOR inhibition can partially reverse aspects of immune aging. The doses were lower and given for a shorter period than those used to prevent transplant rejection.

The study · 1

Mannick et al., mTOR inhibition improves immune function in the elderly · Sci Transl Med 2014;6(268):268ra179

Longevity And Mortality

Rapamycin started late raised mouse lifespan about 9% in males and 14% in femalesPreliminary

In plain terms

Rapamycin is the most reliable drug known for extending lifespan in mice, and it works even when started in old age. The finding has been repeated in a rigorous multi-site program, which is why it is the flagship animal result.

In detail

Harrison and colleagues (2009) reported that rapamycin fed to genetically heterogeneous mice starting at 600 days of age extended median and maximal lifespan in both sexes, a striking result because the treatment began late in life. Miller and colleagues (2011) confirmed lifespan extension with rapamycin in the same multi-site Interventions Testing Program while resveratrol and simvastatin did not extend life, strengthening the finding through independent replication. The Interventions Testing Program tests compounds at three sites in a genetically diverse mouse population specifically to reduce false positives.

The studies · 2

Harrison et al., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice · Nature 2009;460(7253):392-395

Miller et al., Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice · J Gerontol A Biol Sci Med Sci 2011;66(2):191-201

A threefold higher dose extended mouse lifespan about 23% in males and 26% in femalesPreliminary

In plain terms

The mouse lifespan effect grows at higher doses and differs between males and females, which shows the benefit is dose related and is not simply the same as eating less.

In detail

Miller and colleagues (2014) tested higher rapamycin doses in genetically heterogeneous mice and found larger lifespan gains than at the original dose, with a clear dose-response and consistent sex differences in the size of the effect. The authors also reported that the metabolic changes accompanying rapamycin differed from those produced by dietary restriction, indicating the two interventions extend life through at least partly separate routes.

The study · 1

Miller et al., Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction · Aging Cell 2014;13(3):468-477

Cognition

Chronic rapamycin improved learning and lowered anxiety-like behavior in micePreliminary

In plain terms

In mice, long-term rapamycin improved learning and reduced anxiety-like behavior. It is an early animal signal for the brain, not a demonstrated effect in people.

In detail

Halloran and colleagues (2012) gave mice chronic rapamycin across the lifespan and found improvements on tests of learning and memory together with reduced anxiety-like and depressive-like behaviors, accompanied by higher brain levels of several neurotransmitters. The work is an early mechanistic lead for effects of mTOR inhibition on the aging brain, not evidence of cognitive benefit in humans.

The study · 1

Halloran et al., Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice · Neuroscience 2012;223:102-113

Muscle And Strength

Eight weeks of rapamycin showed no clear physical-performance gain in healthy older adultsPreliminary · no effect

In plain terms

A small, short human trial found rapamycin was tolerable in healthy older adults but showed no clear improvement in physical function. Human longevity trials with physical-function endpoints are only now emerging.

In detail

Kraig and colleagues (2018) randomized 25 healthy older adults to eight weeks of rapamycin or placebo to test feasibility and safety, tracking immune, physical performance and cognitive measures. The drug was tolerated without serious adverse events, and no clear change was seen in physical performance, cognition or most immune measures in this small, short study, which was designed to establish feasibility, not to detect an effect. The one consistent laboratory signal was statistically significant decrements in several red-cell measures, including hemoglobin, hematocrit and red blood cell count, which the authors judged not clinically significant over the short study. Larger off-label efforts such as the PEARL trial, which uses physical-function endpoints, remain preliminary.

The study · 1

Kraig et al., A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort · Exp Gerontol 2018;105:53-69

The Off-Label Gap

Between the strong animal data and the thin human data sits a large off-label experiment. Most users take rapamycin on an intermittent schedule. Transplant medicine, by contrast, uses continuous dosing. The off-label idea is that spaced doses might keep the growth-slowing effect while easing the load on the immune system. That reasoning is a hypothesis drawn from animal work and pharmacology. No completed human longevity trial has confirmed it.

The human function data is small and short. A feasibility trial gave healthy older adults an eight-week course and found it tolerable. Over that span it produced no clear change in physical performance, cognition, or most immune measures. Its one consistent laboratory signal was a statistically significant drop in several red-cell measures, including hemoglobin, hematocrit, and red blood cell count. The investigators judged that drop not clinically significant over the short trial. Larger efforts such as the PEARL trial, which uses physical-function endpoints, are still preliminary.

Rapamycin is a prescription immunosuppressant, not a supplement, and no completed human trial establishes a safe or effective dose for slowing aging in a healthy person.

The animal case is strong, the human aging case is early, and the best schedule for a healthy person is unknown. The risks are documented in the Cautions below.

Go Deeper

• The biology of aging: where rapamycin and mTOR sit among the hallmarks of aging, and how to read an animal drug result against the human evidence.
• Autophagy: the cellular recycling process rapamycin switches on by inhibiting mTOR, and the mechanism much of the longevity case runs through.
• Peptides: another category where a few approved drugs sit alongside a large off-label market, and how to keep the two apart.
• IV therapy and NAD: a neighboring anti-aging pitch, and the same distinction between moving a marker and changing an outcome.

The Chinese Medicine View

Rapamycin is a modern isolate, so no classical Chinese entry exists for it. No historical text assigns it a channel, a temperature, or a flavor, and no traditional formula contains it. Nothing suggests any herb or formula reproduces what rapamycin does.

The tradition does reason about the territory the drug acts on. In cellular terms, rapamycin mimics a fasting signal: it lowers building in a well-fed cell and clears out what is worn. That sits close to a deep theme in Chinese medicine, the idea in Yang Sheng, the cultivation of life, that moderation and restraint conserve the body's reserves. Classical counsel to stop eating before fullness, and the long practice of periodic simplicity in eating, reach the same place by observation. Nutrient-sensing biology points the same way: constant abundance and constant growth signaling appear to accelerate aging.

The tradition also holds a caution that fits here. Tonifying, or building the body up, is appropriate only when there is a true deficiency and the person can assimilate what is given. Push past that, and the same effort depletes the body instead of restoring it. A drug that suppresses the immune system and disturbs the transformation of nourishment is, in that framing, a powerful intervention with a cost.

The drug stands or falls on the trials. The animal trials are numerous; trials in healthy humans are almost none.

Cautions

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

At treatment doses, sirolimus commonly caused mouth ulcers, raised cholesterol and diarrhea

McCormack and colleagues (2011) randomized 89 women with lymphangioleiomyomatosis to sirolimus or placebo for a year. Sirolimus stabilized lung function during treatment, and the trial documented its adverse-effect profile: mucositis (mouth ulcers), gastrointestinal effects such as diarrhea and nausea, acneiform rash, hypercholesterolemia and peripheral edema occurred more often than with placebo. The lung-function benefit was lost after the drug was stopped, underlining that these effects accompany continuous therapeutic dosing.McCormack et al., Efficacy and safety of sirolimus in lymphangioleiomyomatosis

Prescription drug, immune-suppressing

Rapamycin is a prescription drug whose primary action is to suppress the immune system. At the doses used in transplant medicine it lowers immune defenses enough to raise the risk of infections, including serious ones, and it requires blood-level monitoring and medical oversight. Whatever the longevity hopes attached to it, it belongs in the hands of a clinician who can weigh that risk for a given person.

Infection risk

Because it dampens immune function, rapamycin can make infections more likely and harder to clear. This is the central trade-off of the drug and the reason the aging research uses lower, spaced doses in the hope of reducing it. Whether intermittent dosing avoids meaningful immunosuppression in a healthy person is not established.

Mouth ulcers and impaired wound healing

Mouth ulcers, or mucositis, are among the most common side effects. Rapamycin also slows wound healing, so surgeons often pause it around operations. Anyone facing surgery or dealing with a wound needs a clinician to manage the drug, not a schedule found online.

Effects on blood sugar and lipids

Rapamycin can raise cholesterol and triglycerides and can worsen glucose handling. In animals the metabolic picture is mixed, and in transplant patients these changes are well documented. They are part of the risk that any longevity use has to account for.

Drug interactions

Rapamycin is processed by liver enzymes that many other drugs and even grapefruit affect, so its blood levels can swing up or down when combined with common medications. This is one more reason its use requires a prescriber who knows the full medication list, not self-management.

Not a do-it-yourself longevity drug

If rapamycin interests you, the responsible step is a clinician who can order blood-level monitoring and weigh the risks for you. No home protocol substitutes for that oversight while the aging trials are unfinished.

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

Common Questions

Does rapamycin actually extend lifespan?

Living longer and staying healthy longer are different questions, and rapamycin's mouse data speaks mainly to the first. No human study has followed people long enough to measure either one directly. That is why aging research leans on shorter-term markers instead of years of life, and why a confident human lifespan claim is not yet possible.

Is rapamycin approved for anything?

Yes, for several specific diseases, all covered above. What matters for aging is what is missing from that list: no regulator has approved rapamycin, or any drug, for aging itself. Every longevity use therefore falls outside the label. That gap is the whole reason the practice is called off-label.

Why do some people take rapamycin off-label for aging?

The reasoning is covered above. Off-label has a specific legal meaning: a clinician may legally prescribe an approved drug for a purpose it was never approved for, at their own discretion. That is how rapamycin reaches healthy people while the aging trials are still unfinished. It also means the prescriber and the patient, not a regulator, carry the evidence burden.

What are the main risks of rapamycin?

The specific risks are listed in the Cautions above. The deciding factor is supervision. In its approved uses rapamycin comes with blood-level testing and a clinician watching for infection; someone self-sourcing it for aging has neither. The same molecule therefore carries a different real-world risk depending on whether anyone is monitoring it.

Can a Chinese herb or formula do what rapamycin does?

No. No herb or formula has been shown to inhibit mTOR the way rapamycin does. TheOverlap is a shared idea about restraint, not a shared mechanism. Fasting and dietary restraint engage the same mTOR pathway at no cost, and both are open to anyone.